Video
Author(s):
Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses mitigating selinexor (Xpovio)-related toxicities in relapsed/refractory multiple myeloma.
Selinexor plus dexamethasone is approved for twice-weekly administration for patients with heavily pretreated multiple myeloma. However, because of the significant gastrointestinal (GI) toxicities associated with selinexor, the agent’s second indication is typically preferred. As such, patients with multiple myeloma who have received at least 1 prior therapy can receive up to 100 mg of oral selinexor in combination with bortezomib (Velcade) once weekly.
Appropriate use of prophylactic agents, such as dexamethasone, 5-hydroxytryptamine receptor antagonists, and aprepitant (Emend), can be given to prevent GI toxicities with selinexor, Hari says. Moreover, with adequate prophylactic treatment, plus potential dose escalation and olanzapine (Zyprexa), selinexor has been shown to be tolerable and highly efficacious for patients with relapsed/refractory multiple myeloma who have limited or no treatment options, concludes Hari.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
2 Commerce Drive
Cranbury, NJ 08512